GW Pharma

3 Biotechs With Huge FDA Decisions in June
3 Biotechs With Huge FDA Decisions in June
Motley Fool
biotech
Array Biopharma
encorafenib
binimetinib
GW Pharma
Epidiolex
Incyte
olumiant
Flag link:
This Cannabis-Based Drug Is On the Verge of Making History
This Cannabis-Based Drug Is On the Verge of Making History
Motley Fool
GW Pharma
Epidiolex
CBD
Dravet syndrome
Lennox-Gastaut Syndrome
FDA
Flag link:
A look at The First Company Likely to Market an FDA Approved Cannabinoid in the US
A look at The First Company Likely to Market an FDA Approved Cannabinoid in the US
CP Wire
GW Pharma
Epidiolex
FDA
cannabinoids
Flag link:
FDA Panel Votes To Approve Marijuana-Based Drug For Epilepsy
FDA Panel Votes To Approve Marijuana-Based Drug For Epilepsy
Forbes
FDA
GW Pharma
Epidiolex
epilepsy
advisory panels
Flag link:
GW Pharma riding high as cannabinoid Epidiolex nears first U.S. approval
GW Pharma riding high as cannabinoid Epidiolex nears first U.S. approval
Fierce Biotech
GW Pharma
Epidiolex
FDA
epilepsy
Flag link:
3 Biotechs That Could Get Big Boosts in April
3 Biotechs That Could Get Big Boosts in April
Motley Fool
biotech
GW Pharma
Epidiolex
Incyte
olumiant
baricitinib
Neurocrine Biosciences
Elagolix
Flag link:
3 Blockbuster Drug Launches to Watch In 2018
3 Blockbuster Drug Launches to Watch In 2018
Motley Fool
drug launches
Gilead Sciences
HIV
Biktarvy
Alnylam
Sanofi
Patisiran
Epidiolex
GW Pharma
Flag link:
12 blockbusters: The surging list of $1B-plus drugs rolling out on the market this year might surprise you
12 blockbusters: The surging list of $1B-plus drugs rolling out on the market this year might surprise you
Endpoints
drug launches
Hemlibra
Roche
Biktarvy
Gilead Sciences
Ozempic
Novo Nordisk
Erleada
JNJ
Shingrix
GSK
Patisiran
Alnylam
Sanofi
Epidiolex
GW Pharma
Aimovig
Amgen
Novartis
lanadelumab
Shire
Elagolix
AbbVie
Steglatro
Pfizer
Merck
Sublocade
Indivior
Flag link:
GW Pharma shares dented after cannabinoid drug fails a PhIIa study on focal seizures
GW Pharma shares dented after cannabinoid drug fails a PhIIa study on focal seizures
Endpoints
GW Pharma
clinical trials
cannabinoids
Epidiolex
seizures
Flag link:
The top 10 prospective blockbuster drug launches slated for 2018 — Evaluate
The top 10 prospective blockbuster drug launches slated for 2018 — Evaluate
Endpoints
drug launches
Bictegravir/F/TAF
Gilead Sciences
semaglutide
Novo Nordisk
epacadostat
Incyte
Rova-T
AbbVie
ozanimod
Celgene
apalutamide
JNJ
Elagolix
AVXS-101
AveXis
lanadelumab
Shire
Epidiolex
GW Pharma
Flag link:
After a decade of work, Otsuka and GW part ways on Sativex
After a decade of work, Otsuka and GW part ways on Sativex
BioPharma Dive
Otsuka
GW Pharma
Sativex
cannabindoids
Flag link:
Could Marijuana Stock GW Pharmaceuticals Soar More Than 50%?
Could Marijuana Stock GW Pharmaceuticals Soar More Than 50%?
Motley Fool
GW Pharma
marijuana
Flag link:
A Tiny Biotech Just Dealt a Big Blow to Marijuana's Use in Epilepsy
A Tiny Biotech Just Dealt a Big Blow to Marijuana's Use in Epilepsy
Motley Fool
biotech
marijuana
epilepsy
ZX008
Zogenix
Epidiolex
GW Pharma
seizures
Flag link:
The 1 Word in GW Pharmaceuticals' Q3 Update That Disappointed Investors
The 1 Word in GW Pharmaceuticals' Q3 Update That Disappointed Investors
Motley Fool
GW Pharma
earnings
investors
Flag link:
Zogenix: Could This Be The Greatest Threat to GW Pharmaceuticals?
Zogenix: Could This Be The Greatest Threat to GW Pharmaceuticals?
Motley Fool
Zogenix
GW Pharma
Sativex
Epidiolex
LGS
Dravet syndrome
Flag link:
GW Pharmaceuticals’ Cannabis Drug Show Promise in Late-Stage Clinical Trial of Epilepsy
GW Pharmaceuticals’ Cannabis Drug Show Promise in Late-Stage Clinical Trial of Epilepsy
Xtalks
GW Pharma
cannabis
clinical trials
Epidiolex
epilepsy
Dravet syndrome
Flag link:
3 Reasons GW Pharmaceuticals Stock Could Rise
3 Reasons GW Pharmaceuticals Stock Could Rise
Motley Fool
GW Pharma
Epidiolex
Flag link:
Top 6 Biopharma Gainers of the Past Week
Top 6 Biopharma Gainers of the Past Week
24/7 Wall St
Catabasis
Sarepta Therapeutics
Anavex
Biogen
Array Biopharma
GW Pharma
Flag link:
3 for 3 in PhIII: GW Pharma racing to the FDA after bagging another late-stage epilepsy success
3 for 3 in PhIII: GW Pharma racing to the FDA after bagging another late-stage epilepsy success
Endpoints
GW Pharma
FDA
Epidiolex
epilepsy
Flag link:
Evaluating a GW Pharma Merger, Maybe
Evaluating a GW Pharma Merger, Maybe
Yahoo/24-7
GW Pharma
M&A
Flag link:

Pages